Takeda
650 East Kendall Street
Cambridge
MA
02421
United States
Website: https://www.takeda.com/
Email: info@takeda.com
About Takeda
Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.
For more information, visit https://www.takeda.com.
Stock Symbol: TAK
Science is the foundation for everything we do at Takeda. We connect to our 240- year history and our strong values through our pursuit of life-transforming science where we embrace a culture of collaboration, pursue modalities based on validated targets, evaluate real-world impact and generate data that may enable accelerated development and regulatory pathways.
1433 articles with Takeda
-
Japan's Takeda Pharmaceutical Co. Ltd. (JOBS), U.S. XOMA (US) LLC to Expand Ties; Takeda Would Pay $29 Million
2/10/2009
-
FDA Approves Takeda Pharmaceutical Co. Ltd.'s KAPIDEX(TM) (Dexlansoprazole) Delayed Release Capsules for the Treatment of GERD
2/2/2009
-
Takeda Pharmaceutical Co. Ltd. Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
1/22/2009
-
Review of Takeda Pharmaceutical Co. Ltd.'s Febuxostat New Drug Application Continues Past PDUFA Date
1/20/2009
-
CellCentric Ltd. and Takeda Pharmaceutical Co. Ltd. Collaborate on Epigenetic Programme
1/6/2009
-
Takeda Pharmaceutical Co. Ltd. Says US FDA to Respond on Diabetes Drug by June
12/29/2008
-
Takeda Pharmaceutical Co. Ltd. Starts Japan Phase III Trials for Obesity Drug
12/22/2008
-
Cell Genesys, Inc. and Takeda Pharmaceutical Co. Ltd. (JOBS) Announce Termination of Collaboration Agreement for GVAX Immunotherapy for Prostate Cancer
12/3/2008
-
No Heart Risk Seen with Takeda Pharmaceuticals North America, Inc. Gout Drug Says U.S. FDA
11/21/2008
-
Takeda Pharmaceutical Co. Ltd. (JOBS) Says U.S. Delays Ulcer Drug Decision
10/20/2008
-
FDA Will Not Be Able To Complete Its Review Of Takeda Pharmaceutical Co. Ltd.'s (JOBS) Alogliptin (SYR-322) NDA By The Prescription Drug User Fee Act (PDUFA) Date Of October 27, 2008; Delay Puts PPD, Inc. Payment On Hold
10/10/2008
-
Takeda Pharmaceutical Co. Ltd. Licenses Recombineering Technology From Gene Bridges GmbH
10/7/2008
-
Alnylam Pharmaceuticals Earns $20 Million Payment from Takeda Pharmaceutical Co. Ltd.
10/7/2008
-
Takeda Pharmaceuticals North America, Inc.'s Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed TAK-390MR Data Presented at the
10/6/2008
-
PPD, Inc. Confirms Takeda Pharmaceutical Co. Ltd.'s NDA Submission of Alogliptin in Japan
9/29/2008
-
Takeda Pharmaceutical Co. Ltd. Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
9/24/2008
-
Takeda Pharmaceutical Co. Ltd. Submits a NDA in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
9/24/2008
-
PPD, Inc. Confirms Takeda Pharmaceutical Co. Ltd.'s NDA Submission of Alogliptin and ACTOS® to U.S. FDA
9/24/2008
-
New Programs Added in Antibody Collaboration Between XOMA (US) LLC and Takeda Pharmaceutical Co. Ltd.
9/16/2008
-
Takeda San Francisco, Inc. Appoints Gregory Landes, Ph.D. Vice President of Antibody Research
9/8/2008